Thienyl compounds for inhibition of cell proliferative disorders

Details Thienyl compounds for inhibition of cell proliferative disorders Thienyl compounds for inhibition of cell proliferative disorders

1997-11-17

1999-03-23

Lambkin, Deborah C.

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C07D33312

Patent

active

058861955

ABSTRACT:
The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities.

REFERENCES:
patent: 4870076 (1989-09-01), Heckel et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5166362 (1992-11-01), Forquy et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5512685 (1996-04-01), Jarvinen et al.
patent: 5571810 (1996-11-01), Matsuo et al.
patent: 5726326 (1998-03-01), Hutchings et al.
Aaronson, S. A. "Growth Factors and Cancer," Science 254:1146-1153 (1991).
Arvidsson, A. K. et al., "Tyr-716 in the Platelet-Derived Growth Factor b-Receptor Kinase Insert is Involved in GRB2 Binding and ras Activation," Molecular and Cellular Biology 14:6715-6726, 1991.
Baserga, R. "The Insulin-like Growth Factor I Receptor: a Key to Tumor Growth?" Cancer Research 55:249-252, 1989.
Bisbee, C. "Scatter Factor/Hepatocyte Growth Factor Gene Deletion Leads to Death Knockout Mice," Bioworld Today 2 (1995).
Carraway, L.K. et al., "The erbB3 Gene Product is a Receptor for Heregulin," The Journal of Biological Chemistry 269:14303-14306 (1994).
Carraway, K.L. et al., "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling," Cell 78:5-8 (1994).
Claesson-Welsh, L. "Signal Transduction by the PDGF Receptors," Progress in Growth Factor Research 5:37-54 (1994).
Cullen, K.J. et al., "Insulinlike Growth Factors in Human Malignancy," Cancer Investigation 9:443-454 (1991).
Dati, C. et al., "Inhibition of c-erB-2 Oncogene Expression by Estorgens in Human Breast Cancer Cells," Oncogene 5:1001-1006 (1990).
Decker, T. et al., "A Quick and Simple Method for Quantitation of Lactate Dehydrogenase Release in Measurements of Cellular Cytotoxicity and Tumor Necrosis Factor (TNF) Activity," J. Imm. Methods 15:61-69 (1988).
de Vries, C. et al., "The fms-like Tyrosine Kinase, A Receptor for Vascular Endotheial Growth Factor," Science 255:989-991 (1992).
Dougall, W. C. et al., "The Neu-oncogene: Signal Transduction Pathways, Transformation Mechanism and Evolving Therapies," Oncogene 9:2109-2123 (1994).
Fendly, B. M., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
eu Gene Product," Cancer Research 50:1550-1558 (1990).
Ferrara, N., et al., "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," Biochemical and Biophysical Research Communications 161:851-858 (1989).
Fingle, E. et al., The Pharmacological Basis of Therapeutics Chapter 1:1-46 (1975).
Floege, J., et al., "Factors Involved in the Regulation of Mesangil Cell Proliferation in vitro and in vivo," Kidney International 43:S-47-S-54 (1993).
Folkman, J. "Tumor Angiogenesis: Therapeutic Implictions," the New England Journal of Medicine 285(18): 1182-1186 (1971).
Folkman, J. "What is the Evidence that Tumors are Angiogenesis Dependent?" Journal of the National Cancer Institute 82:4-6 (1990).
Folkman, J. et al., "Angiogenesis," The Journal of Biological Chemistry 267-10931-10934 (1992) .
Fry, M. J., et al., New Insights into Protein-tyrosine Kinase Receptor Signaling Complexes, Protein Science 2:1785-1797 (1993).
Giordano, S. et al., "The c-met/HGF Receptor in Human Tumors," European Journal of Cancer Prevention 1:45-49 (1992).
Gottardis, M. M., et al., Estradiol-stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen, J. Steroid Biochem. 30:311-314 (1988).
Harris, J.R. et al., "Breast Cancer" New England Journal of Medicine 327:319-328 (1992).
Honegger, A. M. et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-tyrosine Kinase Activity and Alters Cellular Routing," Cell 51:199-209 (1987).
Houck, K. A. et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," The Journal of Biological Chemistry 267-26031-26037 (1992).
Hu, P., et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derive Growth Factor Receptors," Molecular and Cellular Biology 12:981-990 (1992).
Jellinek, D., et al., "Inhibition of Receptor Binding by High-affinity RNA Ligands to Vascular Endothelial Growth Factor," Biochemistry 33:10450-10456 (1994).
Jucker, M., et al., "The Met/hepatocyte Growth Factor Receptor (HGFR) Gene is Overexpressed in Some Cases of Human Leukemia and Lymphoma," Leukemia Research 18:7-16 (1994).
Kashishian, A. et al., "Phosphorylation Sites in the PDGF Receptor with Different Specificites for Binding GAP and P13 Kinase in Vivo," The EMBO J 11:1373-1382 (1992).
Kashishian, A. et al., "Phosphorylation Sites at the C-terminus of the Platelet-derived Growth Factor Receptor Bind Phospholipase Cg1," Molecular Biology of the Cell 4:49-57 (1993).
Kazlauskas, A., et al., The 64-kDa Protein that Associates with the Platelet-derived Growth Factor Receptor b Subunit via Tyr-1009 is the SH2-Containing Phosphotyrosine Phosphatase Syp. Proc. Natl. Acad. Sci. USA 90:6939-6942 (1993).
Kendall, R. L. et al., "Inhibition of Vascular Endothelial Cell Growth Factor Activity by and Endogenously Encoded Souble Receptor," Proc. Natl. Acad. Sci. 90:10705-10709 (1993).
Kim, K. J., et al., "Inhibition of Vascular Endothelial Cell Growth Factor-induced Angiogenesis Supresesses Tumor Growth in vivo," Nature 362:841-844 (1993).
Kinsella, J. L. et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement membrane matrix, Matrigel," Experimental Cell Research 199:56-62 (1992).
Klagsburn, M. et al., "VEGF/VPF: The Angiogenesis Factor Found?" Current Biology 3 :699-702 (1993).
Korzseniewski, C., et al., "An Enzyme-release Assay for Natural Cytoxicity," Journal of Immunological Methods 64:313-320 (1983).
Krywicki et al., "The Insulin-like Growth Factor Family of Ligands, Rceptors, and binding Proteins," Breast Cancer Research and Treatment 22:7-19 (1992).
Mariani, M., et al., "Inhibition of Angiogenesis by PCT26806, a Potent Tyrosine Kinase Inhibitor," Proceedings of the American Assoc. for Cancer Research 35:381 (1994).
Marshall, E. "Search for a Killer: Focus Shifts from Fat to Hormones," Science 259:618-621 (1993).
Millauer, B., et al., "High Affinity VEGF Binding and Developmental Expression Suggest FLK-1 as a major Regulator of Vasculogenesis and Angiogenesis," Cell 72:835-846 91993).
Mosmann, T., "Rapid colormetric Assay for Cellular Growth and Survival Application to Proliferation and Cytotoxicity Assays," Journal of Immunological Methods 65:55-63 (1983).
Natali, P. G. et al., "Expression of the c-Met/HGF Receptor in Human Melanocytic Neoplasms: Demonstration of the Relationship to malignant Melanoma Tumor Progression," Br. J. Cancer 68:746-750 (1993).
Nishmura, R., et al., "Two Signaling Molecules Share a Phosphotyrosine-containing Binding Site in the Platelet-derived Growth Factor Receptor," Molecular and Cellular Biology 13:6889-6896 (1993).
Osborne, C. K., et al., "Effect of Estorgens and Antiestorgens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," Cancer Research 45:584-590 (1985).
Ozzello, L. et al., "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," Europ. J. Cancer 16:553-559 (1980).
Plowman, G. D., et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," DN&P 7:334-339 (1994).
Quinn, T. P. et al., "Fetal Liver Kinase 1 is a Receptor for Vascular Endothelial Growth Factor and is Selectively Expressed in Vascular Endothelium," Proc. Natl. Acad. Sci. USA 90:7533-7537 (1993).
Di Renzo, M. F., et al., "Expression of the Met/HGF Receptor in Normal and Neoplastic Human Tissues," Oncogene 6:1997-2003, 1990.
Di Renzo, M. F. et al., "Expression of the Met/Hepatocyte Growth Factor Receptor in Human Pancreatic Cancer" Cancer Research 55,

Affiliated with

Also associated with

Rating

Thienyl compounds for inhibition of cell proliferative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thienyl compounds for inhibition of cell proliferative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienyl compounds for inhibition of cell proliferative disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2127178